PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för saxagliptin. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

25 hits

Bibliografisk träff 2013-03-01

Simultaneous oral therapeutic and intravenous ¹⁴C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin.

Boulton DW, Kasichayanula S, Keung CF, Arnold ME, Christopher LJ, Xu XS, Lacreta F.

Br J Clin Pharmacol · clinical trial; research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/j.1365-2125.2012.04391.x

Bibliografisk träff 2012-11-09

Saxagliptin overview: special focus on safety and adverse effects.

Ali S, Fonseca V.

Expert Opin Drug Saf · review; journal article · DOI 10.1517/14740338.2013.741584

Bibliografisk träff 2012-11-01

Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats.

Mason RP, Jacob RF, Kubant R, Ciszewski A, Corbalan JJ, Malinski T.

J Cardiovasc Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1097/fjc.0b013e31826be204

Bibliografisk träff 2012-08-01

Overcoming bioanalytical challenges in an Onglyza(®) intravenous [(14)C]microdose absolute bioavailability study with accelerator MS.

Xu XS, Dueker SR, Christopher LJ, Lohstroh PN, Keung CF, Cao KK, Bonacorsi SJ, Cojocaru L, Shen JX, Humphreys WG, Stouffer B, Arnold ME.

Bioanalysis · validation study; journal article · DOI 10.4155/bio.12.171

Bibliografisk träff 2012-07-24

The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial.

Frederich R, McNeill R, Berglind N, Fleming D, Chen R.

Diabetol Metab Syndr · research-article; journal article · DOI 10.1186/1758-5996-4-36

Bibliografisk träff 2012-07-09

Effect of saxagliptin on the pharmacokinetics of the active components of Ortho-Cyclen(®), a combined oral contraceptive containing ethinyl estradiol and norgestimate, in healthy women.

Upreti VV, Hsiang CB, Li L, Xu X, LaCreta FP, Boulton DW.

Diabetes Obes Metab · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1111/j.1463-1326.2012.01635.x

Bibliografisk träff 2012-07-01

Pharmacokinetic study of saxagliptin in healthy Chinese subjects.

Li H, Yang L, Tou CK, Patel CG, Zhao J.

Clin Drug Investig · clinical trial; journal article · DOI 10.2165/11598760-000000000-00000

Bibliografisk träff 2012-05-28

Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes.

Poucher SM, Cheetham S, Francis J, Zinker B, Kirby M, Vickers SP.

Diabetes Obes Metab · research support, non-u.s. gov't; journal article · DOI 10.1111/j.1463-1326.2012.01619.x

Bibliografisk träff 2012-04-10

Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.

Su H, Boulton DW, Barros A, Wang L, Cao K, Bonacorsi SJ, Iyer RA, Humphreys WG, Christopher LJ.

Drug Metab Dispos · journal article · DOI 10.1124/dmd.112.045450

Bibliografisk träff 2012-04-04

Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.

Wang A, Dorso C, Kopcho L, Locke G, Langish R, Harstad E, Shipkova P, Marcinkeviciene J, Hamann L, Kirby MS.

BMC Pharmacol · comparative study; research-article; journal article · DOI 10.1186/1471-2210-12-2

Bibliografisk träff 2012-03-01

Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial.

Pan CY, Yang W, Tou C, Gause-Nilsson I, Zhao J.

Diabetes Metab Res Rev · clinical trial, phase iii; multicenter study; randomized controlled trial; journal article · DOI 10.1002/dmrr.1306

Bibliografisk träff 2012-03-01

Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis.

Erhardt W, Bergenheim K, Duprat-Lomon I, McEwan P.

Clin Drug Investig · research support, non-u.s. gov't; journal article · DOI 10.2165/11597060-000000000-00000

Bibliografisk träff 2012-03-01

Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.

Barnett AH, Charbonnel B, Donovan M, Fleming D, Chen R.

Curr Med Res Opin · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1185/03007995.2012.665046

Bibliografisk träff 2012-02-15

Development of a rapid UPLC-MS/MS method for quantification of saxagliptin in rat plasma and application to pharmacokinetic study.

Gao JW, Yuan YM, Lu YS, Yao MC.

Biomed Chromatogr · journal article · DOI 10.1002/bmc.2720

Bibliografisk träff 2012-02-08

Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.

Scheen AJ.

Expert Opin Drug Metab Toxicol · review; journal article · DOI 10.1517/17425255.2012.658771

Bibliografisk träff 2012-02-06

Liquid chromatography and tandem mass spectrometry method for the quantitative determination of saxagliptin and its major pharmacologically active 5-monohydroxy metabolite in human plasma: method validation and overcoming specific and non-specific binding at low concentrations.

Xu XS, Demers R, Gu H, Christopher LJ, Su H, Cojocaru L, Boulton DW, Kirby M, Stouffer B, Humphreys WG, Arnold ME.

J Chromatogr B Analyt Technol Biomed Life Sci · research support, non-u.s. gov't; journal article · DOI 10.1016/j.jchromb.2012.01.033

Bibliografisk träff 2012-01-18

Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage.

Fonseca V, Zhu T, Karyekar C, Hirshberg B.

Diabetes Obes Metab · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1111/j.1463-1326.2011.01553.x

Bibliografisk träff 2012-01-16

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data.

Cobble ME, Frederich R.

Cardiovasc Diabetol · meta-analysis; research support, non-u.s. gov't; review-article; review; journal article · DOI 10.1186/1475-2840-11-6

Bibliografisk träff 2012-01-01

Metformin + saxagliptin for type 2 diabetes.

Scheen AJ.

Expert Opin Pharmacother · review; journal article · DOI 10.1517/14656566.2012.642867

Bibliografisk träff 2012-01-01

Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU.

Yang LP.

Drugs · review; journal article · DOI 10.2165/11208160-000000000-00000

Bibliografisk träff 2012-01-01

A pharmacometric approach to quantify the impact of chronic kidney disease and hemodialysis on systemic drug exposure: application to saxagliptin.

Zhang L, Boulton DW, Pfister M.

J Clin Pharmacol · journal article · DOI 10.1177/0091270011415627

Bibliografisk träff 2011-12-27

Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis.

Gerrald KR, Van Scoyoc E, Wines RC, Runge T, Jonas DE.

Diabetes Obes Metab · meta-analysis; comparative study; systematic review; journal article · DOI 10.1111/j.1463-1326.2011.01540.x

Bibliografisk träff 2011-12-01

Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies.

Schwartz SL.

Ann Med · research support, non-u.s. gov't; review; journal article · DOI 10.3109/07853890.2011.603701

Bibliografisk träff 2011-11-08

The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland.

Grzeszczak W, Czupryniak L, Kolasa K, Sciborski C, Lomon ID, McEwan P.

Diabetes Technol Ther · research support, non-u.s. gov't; validation study; journal article · DOI 10.1089/dia.2011.0092

Bibliografisk träff 2011-10-15

Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden.

Granström O, Bergenheim K, McEwan P, Sennfält K, Henriksson M.

Prim Care Diabetes · comparative study; randomized controlled trial; journal article · DOI 10.1016/j.pcd.2011.09.003